Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899132 · ClinicalTrials.gov registry record
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- 180
- Enrollment target
NCT00899132 is a clinical trial that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 180 participants.
The verdict
NCT00899132 was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.
Interventions
- GENETIC protein expression analysis
- OTHER immunologic technique
- GENETIC in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899132
The ClinicalTrials.gov registry entry for NCT00899132 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which protein expression analysis is the first listed.
NCT00899132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899132 about?
NCT00899132 is a clinical study titled "Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestin...
What is the current status of trial NCT00899132?
This trial is currently terminated. The enrollment target is 180 participants. The study started on 2007-02. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00899132?
The interventions under investigation include: protein expression analysis (GENETIC), immunologic technique (OTHER), in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00899132?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.